Lou focuses on identifying emerging biopharmaceutical, device and platform technology companies. He sits on the Boards of Ascenta Therapeutics, Century Hospice, Horizon Pharma, Orexigen Therapeutics, SGX Pharmaceuticals, Sonexa Therapeutics and Zogenix. He is responsible for ScaleVP’s investments in Dynavax Technologies (NASDAQ: DVAX), Prestwick Pharmaceuticals, Seattle Genetics (NASDAQ: SGEN) and Somaxon (NASDAQ: SOMX).
Lou joined ScaleVP in 1997 from Gilead Sciences, where he held positions in research, project management, business development and sales. While at Gilead, Lou was the project manager for Gilead’s approved antiviral drug, Vistide, and was responsible for the discovery of Gilead’s novel thrombin aptamer. Prior to Gilead, he was a research associate at Genentech.
Aug, 2006 - Current (about 10 years)
Board & Advisor Roles (8)Update
|Jan, 2014||PowerVision||$20M / Series D||Lexington Partners|
|Oct, 2010||New Century Hospice||$20M / Series A (Lead)||Scale Venture Partners|
|Jul, 2010||Zogenix||$15M / Venture||Scale Venture Partners|
|Oct, 2009||Zogenix||$35.96M / Series B||Scale Venture Partners|
|Feb, 2009||diaDexus||$9.2M / Series F||Scale Venture Partners|
|Jan, 2008||Sonexa Therapeutics||$30M / Series A (Lead)||Scale Venture Partners|
|Jan, 2008||Zogenix||$18M / Series B||Scale Venture Partners|
|Jan, 2007||diaDexus||$40M / Series E (Lead)||Scale Venture Partners|
|Aug, 2006||Zogenix||$60M / Series A||Scale Venture Partners|